Cell therapy for spinal cord injury by using human iPSC-derived region-specific neural progenitor cells

Mol Brain. 2020 Sep 3;13(1):120. doi: 10.1186/s13041-020-00662-w.

Abstract

The transplantation of neural progenitor cells (NPCs) derived from human induced pluripotent stem cells (iPSCs) has beneficial effects on spinal cord injury (SCI). However, while there are many subtypes of NPCs with different regional identities, the subtype of iPSC-derived NPCs that is most appropriate for cell therapy for SCI has not been identified. Here, we generated forebrain- and spinal cord-type NPCs from human iPSCs and grafted them onto the injured spinal cord in mice. These two types of NPCs retained their regional identities after transplantation and exhibited different graft-host interconnection properties. NPCs with spinal cord regional identity but not those with forebrain identity resulted in functional improvement in SCI mice, especially in those with mild-to-moderate lesions. This study highlights the importance of the regional identity of human iPSC-derived NPCs used in cell therapy for SCI.

Keywords: Region-specific neural progenitors; Spinal cord injury; Stem cell therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal
  • Cell Differentiation
  • Cell Line
  • Cell- and Tissue-Based Therapy*
  • Humans
  • Induced Pluripotent Stem Cells / cytology*
  • Mice, Inbred NOD
  • Mice, SCID
  • Motor Activity
  • Neural Stem Cells / cytology*
  • Neural Stem Cells / transplantation*
  • Organ Specificity*
  • Recovery of Function
  • Spinal Cord / pathology
  • Spinal Cord / physiopathology
  • Spinal Cord / ultrastructure
  • Spinal Cord Injuries / pathology
  • Spinal Cord Injuries / physiopathology
  • Spinal Cord Injuries / therapy*